Lataa...
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Today, monoclonal antibodies (mAbs) are a widespread and necessary tool for biomedical science. In the hematological cancer field, since rituximab became the first mAb approved by the Food and Drug Administration for the treatment of B-cell malignancies, a number of effective mAbs targeting lineage-...
Tallennettuna:
| Julkaisussa: | Front Immunol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5776327/ https://ncbi.nlm.nih.gov/pubmed/29387053 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.01936 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|